Clinical trials: Steroid Refractory Acute Graft Versus Host Disease
Steroid-refractory Acute Graft-versus-host Disease
Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease
The purpose of this trial is the comparative evaluation of overall response rate (ORR) in paediatric participants with steroid-refractory acute graft-versus-host disease (SR-aGvHD) at Visit Day 28 after treatment with MC0518 or…
- Trial name
- BALDER (NCT06075706)
- Testing
- MC0518, BAT
- Where
- 36 sites in France, Germany and 3 more
- Volunteers
- 49 people
- Sponsor
- medac GmbH
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Graft vs. Host Disease
Brentuximab Vedotin for Steroid Refractory GvHD
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational drug. Phase I studies also try to define the appropriate dose of the investigational drug to use for further studies.
- Trial name
- NCT01596218
- Testing
- Brentuximab Vedotin
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Colitis, Ulcerative
Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis
This study aims to examine patients with acute severe UC who are refractory to intravenous corticosteroids and determine whether a strategy of using upadacitinib first followed by infliximab in upadacitinib non-responders is…
- Trial name
- RESCUE UC (NCT06660693)
- Testing
- Upadacitinib Oral Product
- Where
- Canada
- Volunteers
- 134 people
- Sponsor
- McMaster University
Graft Versus Host Disease
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to evaluate the efficacy and gather additional safety information for Prochymal® in participants who have failed to respond to steroid treatment of Grades B-D acute GVHD.
- Trial name
- NCT00366145
- Testing
- Prochymal®, Standard of Care for GVHD
- Where
- 70 sites in United States, Australia and 4 more
- Volunteers
- 260 people
- Sponsor
- Mesoblast, Inc.
Graft-Versus-Host Disease, GVHD
Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease
Graft-versus-host-disease (GVHD) is a major complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT) which may cause acute life-threatening morbidity or chronic disabilities.
- Conditions
- Graft-Versus-Host Disease, GVHD, Allogeneic Hematopoietic Transplant, Disorder Related to Transplantation
- Trial name
- GVHD-MSC (NCT01549665)
- Testing
- Human umbilical cord blood-derived mesenchymal stem cells
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
GVHD
Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)
The aim of this trial is to assess safety and efficacy of apraglutide in subjects with steroid refractory gastrointestinal aGVHD.
- Trial name
- NCT05415410
- Testing
- Apraglutide
- Where
- 13 sites in United States, Germany and 2 more
- Volunteers
- 31 people
- Sponsor
- VectivBio AG
Steroid-refractory aGvHD Subsequent to Allogeneic Hematopoietic Cell Transplantation
A Study Evaluating the Efficacy and Safety of Neihulizumab vs "Conventional Treatment" to Treat Sr-aGvHD
This study is to assess the efficacy of Neihulizumab versus "conventional therapy" and to evaluate safety, pharmacokinetics and immunogenicity in treating steroid-refractory acute Graft-vs-Host Disease
- Trial name
- NCT02694770
- Testing
- Neihulizumab Treatment, Conventional Treatment
- Where
- 2 sites in United States
- Sponsor
- AbGenomics B.V Taiwan Branch
Graft Versus Host Disease
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
- Trial name
- T-REG (NCT01453140)
- Testing
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hackensack Meridian Health
Acute Graft Versus Host Disease
A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant
This study is to establish the safety, determine if there is an improvement in steroid refractory acute graft-vs-host disease (aGvHD) compared to historical cohorts, and determine the changes of aGvHD-associated T-cell clones in…
- Trial name
- NCT02436460
- Testing
- AbGn-168H
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Graft Versus Host Disease
Identification of Novel Targetable Kinases in SR-a GvHD
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
- Trial name
- NCT04342442
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Freiburg
Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Moxibustion for Steroid-Refractory Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
This study is a prospective, multicenter, open-label, phase II clinical trial designed to evaluate the safety and efficacy of moxibustion in patients with steroid-refractory acute graft-versus-host disease (SR-aGVHD) following…
- Conditions
- Steroid-Refractory Acute Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Graft-Versus-Host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- NCT07572669
- Testing
- Moxibustion, Moxibustion Twice Daily Plus Best Available Treatment (BID Group), Best Available Treatment (BAT)
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Graft Vs Host Disease
ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD
The Balance study will assess the safety, tolerability, and efficacy of an investigational drug called ALPN-101 in adults with steroid-resistant or steroid-refractory acute graft versus host disease (aGVHD).
- Trial name
- Balance (NCT04227938)
- Testing
- ALPN-101
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Alpine Immune Sciences, Inc.
Steroid Refractory GVHD
Evaluation of EFficacy and SaFEty of Leukotac (Inolimomab) in Pediatric Patients With SR-aGvHD
A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)
- Trial name
- EiFFEL (NCT04289103)
- Testing
- Inolimomab (Leukotac)
- Volunteers
- 65 people
- Sponsor
- ElsaLys Biotech
Graft Versus Host Disease, Cancer
Extracorporeal Photopheresis for Acute Graft Versus Host Disease
The purpose of this research study is to evaluate the safety and feasibility of extracorporeal photopheresis (ECP) in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in children.
- Conditions
- Graft Versus Host Disease, Cancer, Stem Cell Transplantation
- Trial name
- NCT00179855
- Testing
- Extracorporeal Photopheresis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Acute Graft-Versus-Host Disease
A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
This is an single-arm, Phase II multi-center study. The purpose of this study is to assess the efficacy and safety of Jaktinib in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease.
- Trial name
- NCT04971551
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD
A study to evaluate the safety and preliminary efficacy of iMSC in subjects with SR-aGVHD
- Trial name
- NCT06321198
- Testing
- iMSC
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Anhui Provincial Hospital
Ulcerative Colitis
Tofacitinib Versus Cyclosporine for Steroid Refractory Acute Severe Ulcerative Colitis
This randomised trial plans to compare oral tofacitinib with intravenous cyclosporine in patients with acute severe ulcerative colitis who have failed to respond to intravenous steroids
- Trial name
- TOCASU (NCT05112263)
- Testing
- Tofacitinib, Cyclosporine
- Volunteers
- 96 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Steroid-refractory Acute Graft-versus-host Disease
A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment
It is a phase I/II clinical study to evaluate the safety, tolerability and preliminary efficacy of VUM02 Injection in patients with acute graft-versus-host disease (aGvHD) who have failed systemic steroid therapy.
- Trial name
- ESTEVS-I/II (NCT06677255)
- Testing
- VUM02 Injection (UC-MSCs)+BAT, The control group with Best Available Therapy (BAT)
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Wuhan Optics Valley Vcanbiopharma Co., Ltd.